Literature DB >> 2240060

Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies.

G Ruggieri1, P Barsotti, G Coppola, C Spinelli, A Balducci, F R Ventola, G d'Adamo, M V Tata, V Marinozzi.   

Abstract

A young woman presented with nephrotic syndrome due to membranous nephropathy and a localized form of giant lymph node hyperplasia (Castleman's disease) occurring as a large intra-abdominal mass. Five months after surgical removal of the mass, only mild proteinuria persisted. Twenty months later a second kidney biopsy showed a near-normal morphology. Six years later the patient was free of symptoms and had normal urinalysis. Reviewing the pertinent literature, it seems to be the first case of a biopsy-proven cure of membranous nephropathy in a patient with membranous nephropathy and Castleman's disease.

Entities:  

Mesh:

Year:  1990        PMID: 2240060     DOI: 10.1159/000168127

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

Review 1.  Renal complications of Castleman's disease: report of two cases and analysis of 75 cases.

Authors:  Xiang-Gui Yuan; Wen Hu; Fei-Fei Chen; Bin-Feng Huang; Xiao-Ying Zhao
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

2.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

3.  Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.

Authors:  M C Kinney; D S Hummell; P M Villiger; A Hourigan; L Rollins-Smith; A D Glick; A R Lawton
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

Review 4.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

5.  UCD with MCD-like inflammatory state: surgical excision is highly effective.

Authors:  Miao-Yan Zhang; Ming-Nan Jia; Jia Chen; Jun Feng; Xin-Xin Cao; Dao-Bin Zhou; David C Fajgenbaum; Lu Zhang; Jian Li
Journal:  Blood Adv       Date:  2021-01-12

6.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

7.  [Analysis of the clinicopathologic features as well as diagnosis and treatment of 59 patients with Castleman disease].

Authors:  J Wang; L J Liang; Y M Wang; Z Y Mei; Y Z Liu; L N Liu; B J Fang; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 8.  Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.

Authors:  Ryosuke Saiki; Kan Katayama; Yosuke Hirabayashi; Keiko Oda; Mika Fujimoto; Tomohiro Murata; Ayako Nakajima; Kaoru Dohi
Journal:  BMC Nephrol       Date:  2021-06-09       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.